A Comprehensive Review of Sulfacetamide sodium's R&D Innovations and Drug Target Mechanism

Sulfacetamide sodium's R&D Progress

Sulfacetamide Sodium is a small molecule drug that primarily targets the enzyme dihydropteroate synthase (DHPS). It is used in the treatment of various infectious diseases, eye diseases, skin and musculoskeletal diseases, and urogenital diseases. The active indications for this drug include blepharitis, conjunctivitis, trachoma, dermatitis (seborrheic), and acne vulgaris.

The highest R&D phase of this drug is approved globally. The drug received its first approval in December 1996 in the United States.

Sulfacetamide Sodium is commonly used in ophthalmic formulations for the treatment of eye infections such as conjunctivitis and trachoma. It works by inhibiting the growth of bacteria that cause these infections. Additionally, it is used in dermatological formulations for the treatment of dermatitis, including seborrheic dermatitis, and acne vulgaris. The drug's mechanism of action in these conditions involves reducing inflammation and controlling bacterial growth on the skin.

The approval of Sulfacetamide Sodium in multiple therapeutic areas highlights its versatility and effectiveness in treating various diseases. Infectious diseases, eye diseases, skin and musculoskeletal diseases, and urogenital diseases are all areas where this drug has demonstrated clinical efficacy.

Since its first approval in 1996, Sulfacetamide Sodium has been widely used and has established a strong track record of safety and efficacy. Its long history of use and approval in different countries further supports its reliability and effectiveness.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Mechanism of Action for Sulfacetamide sodium: DHPS inhibitors

DHPS inhibitors are a type of drug that target and inhibit the enzyme dihydropteroate synthase (DHPS). DHPS is an essential enzyme involved in the synthesis of folate, which is crucial for the production of DNA and other important cellular processes. By inhibiting DHPS, these inhibitors disrupt the folate synthesis pathway in bacteria, parasites, or fungi, leading to their growth inhibition or death.

From a biomedical perspective, DHPS inhibitors are primarily used as antimicrobial agents. They are commonly employed in the treatment of bacterial infections caused by pathogens such as Escherichia coli and Staphylococcus aureus. By specifically targeting the DHPS enzyme in bacteria, these inhibitors effectively hinder their ability to synthesize folate, ultimately preventing their proliferation and combating the infection.

DHPS inhibitors can also be used as antiparasitic agents, particularly in the treatment of malaria. The parasite responsible for malaria, Plasmodium falciparum, relies on the DHPS enzyme for folate synthesis. By inhibiting DHPS, these inhibitors disrupt the parasite's ability to produce folate, thereby inhibiting its growth and replication.

Overall, DHPS inhibitors play a crucial role in combating bacterial infections and parasitic diseases by selectively targeting the DHPS enzyme and disrupting folate synthesis in the pathogens.

Drug Target R&D Trends for Sulfacetamide sodium

According to Patsnap Synapse, as of 4 Sep 2023, there are a total of 37 DHPS drugs worldwide, from 41 organizations, covering 65 indications, and conducting 304 clinical trials.

The current competitive landscape of the target DHPS is characterized by the presence of multiple companies with varying levels of R&D progress. AbbVie, Inc., Novartis AG, and Sun Pharmaceutical Industries Ltd. are among the companies growing fastest under this target. The highest stage of development is the Approved phase, with Small molecule drugs being the most rapidly progressing drug type. The indications for the drugs under the target DHPS cover a wide range of infectious diseases and conditions. China and the United States are the countries with the highest number of drugs in the Approved phase, indicating significant progress in these regions. Overall, the target DHPS shows promise for future development in the pharmaceutical industry.

👇Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target

Conclusion

In summary, Sulfacetamide Sodium is a small molecule drug that targets DHPS and is approved for use in the treatment of infectious diseases, eye diseases, skin and musculoskeletal diseases, and urogenital diseases. Its active indications include blepharitis, conjunctivitis, trachoma, dermatitis (seborrheic), and acne vulgaris. With its broad therapeutic applications and established safety profile, Sulfacetamide Sodium continues to be an important drug in the pharmaceutical industry.